Linaclotide is currently being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C), chronic constipation (CC), and other gastrointestinal disorders. Linaclotide is currently undergoing Phase 2b clinical testing in patients with IBS-C and CC. In earlier clinical studies, linaclotide demonstrated improved bowel function in patients with IBS-C and CC. Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism distinct from previously developed products for IBS-C and CC. In Phase 2 trials, linaclotide improved bowel function as measured by both complete spontaneous bowel movements and spontaneous bowel movements in patients with CC and IBS-C. Factors that could cause or contribute to such differences include, but are not limited to the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, challenges relating to intellectual property protection, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in Forest Laboratories’ SEC reports, including its Annual Reports on Form 10-K for the fiscal year ended March 31, 2007 and Quarterly Reports on Form 10-Q for the period ended June 30, 2007 . read more
Technorati Tags: linaclotide, ibsc, cc, microbia, patients, , anxiety disorder news
This entry was posted
on Thursday, September 20th, 2007 at 4:08 am and is filed under Anxiety Disorder News.
You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.
Loading ...
